Oncogenic and incidental HPV types associated with histologically confirmed cervical intraepithelial neoplasia in HIV-positive and HIV-negative South African women

M C van Aardt,1 FCOG (SA); G Dreyer,1 PhD; L C Snyman,1 FCOG (SA); K L Richter,2 FCPath (SA); P Becker,2 PhD; S M Mojaki,1 FCOG (SA)

1 Gynaecological Oncology Unit, Department of Obstetrics and Gynaecology, School of Medicine, Faculty of Health Sciences, University of Pretoria, South Africa
2 Department of Medical Virology, School of Medicine, Faculty of Health Sciences, University of Pretoria; National Health Laboratory Service, Pretoria, South Africa
3 Biostatistics Unit, South African Medical Research Council, Pretoria

Corresponding author: M C van Aardt (mc@vanaardt.net)

Background. In Africa, data on the relationship between oncogenic human papillomavirus (HPV) types, immune status and cervical preinvasive lesions are lacking.

Methods. We investigated low-risk (lrHPV) and high-risk (hrHPV) HPV types in a cohort of women with cervical intraepithelial neoplasia (CIN) II/III confirmed on histological examination, in an urban setting with a high prevalence of HIV infection.

Results. Of 270 women with confirmed CIN II/III, 45 were HIV-negative and 225 HIV-positive. HIV-infected women had significantly more HPV type infections, including all HPV (p<0.001) and hrHPV (p=0.014) types. The prevalences of one or more hrHPV type/s were 93.3% and 92.9% in HIV-negative and positive patients, respectively. The most prevalent hrHPV type among HIV-negative women was HPV 16, followed by HPV 52, 31, 35 and 58. Among HIV-positive women, HPV 16 was followed by HPV 58, 35, 51 and 52. Not yet qualifying for highly active antiretroviral therapy (HAART) (CD4 count >350 cells/μL) or having received HAART for ≥12 months were negatively associated with HPV 18, 33, 45, 51, 52, 59 and 82.

Conclusions. In South Africa, burdened by the HIV pandemic, high numbers of high- and low-risk HPV type infections are present in women with cervical preneoplasia. HPV type distribution differs among varying levels of HIV-induced immune depletion.


Cervical cytological examination is limited to inspection of cells, and the diagnosis of cervical intraepithelial neoplasia (CIN) requires the examination of cervical tissue to make a histological diagnosis. The risk of progression to cervical cancer is greatest for women with CIN III.[11]

One of the known predisposing causes for these preneoplastic changes is persistent infection with one or more of the human papillomavirus (HPV) types. The immune system’s inability to resist changes plays a vital role in the development of cervical carcinoma.[13] Immunocompromised individuals have an increased risk of cervical neoplasia.[14]

Globally, with an estimated 33 million people infected, the HIV/AIDS pandemic is placing a huge burden on healthcare systems and has an enormous impact on women of all ages.[15,16] Approximately 75% of women infected with HIV are living in sub-Saharan Africa, and South Africa (SA) has more HIV-infected women than any other country.[17,18]

It is well established that HIV-infected women have an increased susceptibility to HPV infections and HPV-associated lesions, which include CIN II/III and cervical cancer.[7,13] High-risk HPV (hrHPV) types and CIN are up to four times more common in HIV-positive women.[14] Even though HPV 16 and 18 are responsible for up to 70% of cervical cancers, high-grade cervical lesions are more likely to be associated with non-HPV 16/18 types, especially among HIV-infected women.[15,16]

In women with HIV coinfection, studies have shown that the chance of finding cervical HPV DNA together with abnormal cervical cytology increases as the CD4 cell count decreases.[17] A decline in CD4 cell count and rising HIV viral load are both risk factors for invasive cervical lesions.[18] However, some aspects of the relationship between CIN, immune depletion and the effect of highly active antiretroviral therapy (HAART) are not yet clear.[19]

Some data suggest that despite initiation of HAART and the associated CD4 cell count increase, most women will not experience regression of high-grade (CIN II/III) lesions.[20,21] It appears that immune status has a minimal role in either regression of high-grade lesions or cervical cancer advancing from these lesions. Although immune depletion results in an increased chance of premalignant cervical disease, it seems that other factors contribute to the development of cervical cancer from high-grade cervical lesions.[14,15]

Local data from Africa on the relationship between oncogenic HPV types, immune status and cervical preinvasive lesions are also incomplete.[22] The majority of studies reported in the literature used cytology results synonymously with cervical premalignant changes.[14,21] As cytology is only a screening test, it is important to compare the prevalence of oncogenic HPV types with histopathologically confirmed CIN in women with different levels of immune competence.

Methods

Study design

This was a descriptive study performed at the Gynaecological Oncology Unit at Steve Biko Academic Hospital and the University of Pretoria, SA. Data were obtained from 1 July 2010 to 30 August 2013.
Patients included in the study were women aged ≥18 years, referred for treatment of high-grade squamous intraepithelial lesions (HSILs) detected on conventional cervical cytological examination (Papanicolaou smears) as part of the national screening programme. The study population was representative of women attending public healthcare facilities in the Tshwane region.

Consent process and ethical considerations
Patients received counselling and an information document that explained the method and voluntary nature of the study. During counselling by trained nursing personnel, patients were motivated to undergo HIV testing as per standard departmental management protocols. It was clearly explained to them that testing was voluntary and not a prerequisite for treatment. Planned treatment was also explained: large loop excision of the transformation zone (LLETZ), or directed biopsies if malignancy was suspected. All patients were informed of their HIV results, if applicable. All patients tested for HIV received post-test counselling and were offered a CD4 cell count. These patients were referred to the appropriate antiretroviral therapy clinic for further management. This study was approved by the Research Ethics Committee of the Department of Medical Virology at the University of Pretoria, where HPV DNA testing was performed.

HPV DNA testing
DNA extraction was accomplished by means of the DNA Isolation Kit (Roche Molecular Systems, USA) on the MagNa Pure automated extraction system (Roche, USA). An HPV linear array genotyping kit (Roche Molecular Systems) was used to determine the HPV type. Fifteen high-risk types (HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 70, 73 and 82), three probable high-risk types (HPV 26, 53 and 66) and 19 low/undetermined risk types (HPV 6, 11, 40, 42, 54, 55, 61, 62, 64, 67, 69, 70, 71, 72, 81, 83, 84, IS39 and CP6108) were tested for.[24]

Data capturing and analysis
Data were captured on Excel datasheets (2011, Microsoft, USA), and analysis was performed using Stata statistical software release 11 (StataCorp, USA). Discrete data were mainly binary in nature and summary statistics were frequency, percentage, 95% confidence intervals (CIs), cross-tables and bar charts. Continuous data were summarised using descriptive statistics, means and standard deviations (SDs) along with 95% CIs. Comparison between groups was done with Fisher’s exact test for discrete outcomes and Student’s two-sample t-test or the Wilcoxon rank sum test for continuous outcomes. Testing was done at the 0.05 level of significance. Furthermore, the association between high-risk virus type and HAART use was assessed using logistic regression analysis and adjusted for age and CD4 cell count (logarithmic scale).

Results
The ages of the patients ranged from 21 to 66 years. HIV results were available for all women. Of the 270 women, 225 (83.3%) were HIV-infected and 45 (16.7%) were not infected. There was no significant difference between the two groups with regard to age of diagnosis (p=0.186). CD4 cell counts were available for 205 of the 225 HIV-infected patients (91.1%), and information on HAART treatment and duration was available for all (Fig. 1).

HPV prevalence
The prevalence of any HPV type in patients with CIN II/III was 96.7%, 97.8% among HIV-negative patients and 96.4% among HIV-positive patients. The prevalence of one or more hrHPV type/s was 93.0% in the entire population and 93.3% and 92.9% in HIV-negative and HIV-positive patients, respectively. Twenty-seven HIV-negative patients (60.0%) and 42 HIV-positive patients (18.7%) did not have any low-risk HPV (lrHPV) DNA detected.

Single and multiple hrHPV type infections
A total of 119 HPVs were detected in the 45 HIV-non-infected patients, of which 82 were hrHPV. The total number of HPV types detected in the 225 HIV-infected women was 1 090, with 577 of these categorised as hrHPV types. The number of HPV types detected per patient was significantly greater among HIV-infected v. non-infected patients for all HPV types (p<0.001) and for hrHPV types (p=0.014) (Fig. 1).
One-third (33.3%) of HIV-negative patients had a single HPV type infection, as opposed to only 18 HIV-positive patients (8.0%). Multiple HPV types were detected in 29 HIV-negative patients (64.4%) and 183 HIV-positive patients (81.3%). Three HIV-negative patients (6.7%) had no hrHPV infections, 20 (44.4%) were infected with a single hrHPV type, and the remaining patients (48.9%) had two or more hrHPV type infections. Forty-four patients (19.6%) coinfect ed with HIV had a single hrHPV type detected and 165 (73.3%) had multiple hrHPV type infections.

**HPV type distribution**

In the group as a whole, the most prevalent hrHPV types, in descending order of frequency, were HPV 16, 58, 35, 52, 51 and 45. The most prevalent hrHPV type in the HIV-negative group was HPV 16 (Fig. 2), followed by HPV 52, 31, 35, 58, 18, 33 and 45. HPV 84 was the most prevalent lrHPV type. In the HIV-infected group, HPV 16 was also the most prevalent hrHPV type, followed by HPV 58, 35, 51, 52, 45, 18 and 31. The most prevalent lrHPV type was HPV 62.

---

#### Table 1. hrHPV type distribution in relation to HAART treatment

<table>
<thead>
<tr>
<th>HPV type</th>
<th>HIV- (N=45), n (%)</th>
<th>No ARV (N=35), n (%)</th>
<th>ARV &gt;12 mo (N=43), n (%)</th>
<th>ARV 6 - 12 mo (N=37), n (%)</th>
<th>ARV &lt;6 mo (N=56), n (%)</th>
<th>Start ARV (N=54), n (%)</th>
<th>Total (N=270), n (%)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>16</td>
<td>14 (31.1)</td>
<td>15 (42.9)</td>
<td>11 (25.6)</td>
<td>7 (18.9)</td>
<td>22 (39.3)</td>
<td>19 (35.2)</td>
<td>88 (32.6)</td>
<td>0.206</td>
</tr>
<tr>
<td>18</td>
<td>5 (11.1)</td>
<td>5 (14.3)</td>
<td>7 (16.3)</td>
<td>3 (8.1)</td>
<td>11 (19.6)</td>
<td>11 (20.4)</td>
<td>42 (15.6)</td>
<td>0.570</td>
</tr>
<tr>
<td>31</td>
<td>8 (17.8)</td>
<td>5 (14.3)</td>
<td>3 (7.0)</td>
<td>7 (18.9)</td>
<td>11 (19.6)</td>
<td>8 (14.8)</td>
<td>42 (15.6)</td>
<td>0.562</td>
</tr>
<tr>
<td>33</td>
<td>5 (11.1)</td>
<td>4 (11.4)</td>
<td>10 (23.3)</td>
<td>7 (18.9)</td>
<td>6 (10.7)</td>
<td>7 (13.0)</td>
<td>39 (14.4)</td>
<td>0.494</td>
</tr>
<tr>
<td>35</td>
<td>8 (17.8)</td>
<td>5 (14.3)</td>
<td>10 (23.3)</td>
<td>12 (32.4)</td>
<td>15 (26.8)</td>
<td>15 (27.8)</td>
<td>65 (24.1)</td>
<td>0.434</td>
</tr>
<tr>
<td>39</td>
<td>2 (4.4)</td>
<td>3 (8.6)</td>
<td>4 (9.3)</td>
<td>7 (18.9)</td>
<td>8 (14.3)</td>
<td>7 (13.0)</td>
<td>31 (11.5)</td>
<td>0.384</td>
</tr>
<tr>
<td>45</td>
<td>4 (8.9)</td>
<td>5 (14.3)</td>
<td>9 (20.9)</td>
<td>6 (16.2)</td>
<td>11 (19.6)</td>
<td>10 (18.5)</td>
<td>45 (16.7)</td>
<td>0.659</td>
</tr>
<tr>
<td>51</td>
<td>5 (11.1)</td>
<td>7 (20.0)</td>
<td>8 (18.6)</td>
<td>8 (21.6)</td>
<td>15 (26.8)</td>
<td>14 (25.9)</td>
<td>57 (21.1)</td>
<td>0.433</td>
</tr>
<tr>
<td>52</td>
<td>10 (22.2)</td>
<td>9 (25.7)</td>
<td>9 (20.9)</td>
<td>11 (29.7)</td>
<td>12 (21.4)</td>
<td>7 (13.0)</td>
<td>58 (21.5)</td>
<td>0.492</td>
</tr>
<tr>
<td>56</td>
<td>2 (4.4)</td>
<td>2 (5.7)</td>
<td>6 (13.9)</td>
<td>5 (13.5)</td>
<td>8 (14.3)</td>
<td>8 (14.8)</td>
<td>31 (11.5)</td>
<td>0.412</td>
</tr>
<tr>
<td>58</td>
<td>8 (17.8)</td>
<td>8 (22.9)</td>
<td>8 (18.6)</td>
<td>16 (43.2)</td>
<td>15 (26.8)</td>
<td>13 (24.1)</td>
<td>68 (25.2)</td>
<td>0.141</td>
</tr>
<tr>
<td>59</td>
<td>1 (2.2)</td>
<td>5 (14.3)</td>
<td>2 (4.6)</td>
<td>7 (18.9)</td>
<td>4 (7.1)</td>
<td>6 (11.1)</td>
<td>25 (9.3)</td>
<td>0.092</td>
</tr>
<tr>
<td>68</td>
<td>3 (6.7)</td>
<td>2 (5.7)</td>
<td>3 (7.0)</td>
<td>4 (10.8)</td>
<td>4 (7.1)</td>
<td>7 (13.0)</td>
<td>23 (8.5)</td>
<td>0.826</td>
</tr>
<tr>
<td>73</td>
<td>3 (6.7)</td>
<td>1 (2.9)</td>
<td>2 (4.6)</td>
<td>4 (10.8)</td>
<td>11 (19.6)</td>
<td>6 (11.3)</td>
<td>27 (10.0)</td>
<td>0.111</td>
</tr>
<tr>
<td>82</td>
<td>4 (8.9)</td>
<td>2 (5.7)</td>
<td>5 (11.6)</td>
<td>2 (5.4)</td>
<td>1 (1.8)</td>
<td>4 (7.4)</td>
<td>18 (6.7)</td>
<td>0.451</td>
</tr>
</tbody>
</table>
Association of hrHPV types with HAART use

The prevalence of hrHPV infections was lowest among patients who had been receiving HAART for >12 months. Except for patients who had been receiving HAART for between 6 and 12 months, HPV 16 was the most prevalent hrHPV type among all the different subgroups. Table 1 illustrates the distribution of the different hrHPV types in relation to HAART use.

Patients were divided into two groups. Firstly, patients not yet qualifying for HAART (CD4 count >350 cells/μL) and those who had been receiving HAART for ≥12 months were grouped together. This group was compared with a second group comprising patients in the process of initiating HAART (CD4 count ≤350 cells/μL) and patients who had been receiving HAART for <12 months. Adjusted for age and CD4 cell count on a logarithmic scale, the odds of being infected with HPV 18, 33, 45, 51, 52, 59 and 82 were lower in patients not yet requiring HAART or on HAART for >12 months (Table 2). There was a significant difference for HPV 33 (p=0.029), 59 (p=0.009) and 82 (p=0.034) infections. The odds of having an HPV 73 (p=0.004) infection were significantly lower in patients who had been receiving HAART for <12 months or were in the process of initiating HAART.

Vaccine-preventable infections

We investigated: (i) the prevalence of HPV 16 and/or 18 infections alone, without any other hrHPV coinfections; (ii) only the rates of infection with the seven hrHPV types (HPV 16, 18, 31, 33, 45, 52 and 58) covered by the nine-valent vaccine; and (iii) rates of infection with other hrHPV types not currently specifically covered by vaccines.

As illustrated in Fig. 3, HPV 16 and/or 18 were detected in 124 patients (45.9%) and 214 (79.3%) were infected with HPV 16, 18, 31, 33, 52 and/or 58. Only 37 patients (7.1%) were infected with hrHPV types not included in the nine-valent vaccine. The distribution of hrHPV types between HIV-infected and non-infected patients was very similar.

Discussion

Background

The distribution of HPV types in this cohort of SA women with histologically confirmed CIN II/III is very important. In this study, the positive predictive value for CIN II or more severe changes for patients referred with cytological evidence of HSILs was 83.6%. This highlights the importance of using histopathologically confirmed cervical lesions as the endpoint in the study of cervical disease.[20]

More than 80% of patients in this study were HIV-infected. Although not an AIDS-defining disease like invasive cervical cancer, CIN is regarded as an HIV-related disease.[1] The HIV status of all patients was known, reflecting positively on a high uptake of voluntary HIV testing after appropriate counselling. Although premalignant lesions are more prevalent in HIV-infected women, because they come into contact with the health system relatively often, it is likely that they are better screened than women in the general population, which may explain the high rate of HIV infection in this study. The large percentage of patients infected with HIV also highlights the burden that the HIV/AIDS pandemic places on SA’s healthcare system. Along with the risk of CIN among HIV-infected women, the risk of genital HIV shedding is significantly elevated in the presence of CIN, leading to an increased possibility of HIV transmission.[15]

HPV prevalence

The prevalence of any HPV in the current study was 96.7%. A recent meta-analysis reported the global prevalence of all HPV types in women with CIN II/III as ranging from 86% to 93%.[24] In 2012, the prevalence in Africa was reported as 89% for CIN II and 83% for CIN III.[26]

The prevalence of one or more hrHPV types (93%) was similar to a Botswana study
(92%), but higher than prevalences reported from Kenya (82%) and SA (75%).[17,18,22] A study from South Africa found an hrHPV prevalence of 100% among 18 HIV-positive patients presenting with cytological evidence of HSILs.[19]

The prevalence of hrHPV was higher among patients with a CD4 cell count < 200 cells/µL (97.3%) than among patients with a CD4 cell count of ≥200 cells/µL (90.1%). This is considerably higher than the overall prevalence (84.1%) of HPV infections in HIV-positive women with HSILs reported by Clifford et al.[20]

Single and multiple HPV type infections

Compared with the HIV-negative cohort of patients in the study by McDonald et al.,[21] HIV-negative patients in this study had more multiple hrHPV type infections (49% v. 20%). Women infected with HIV are often coinfected with multiple types, as well as with a broader spectrum of HPV types.[22,23] There were more infections with multiple HPV types in this study than reported by Guan et al.[24]

The 73.3% of HIV-positive patients coinfected with multiple hrHPV types represents a much higher proportion than reported in other studies (27.8 - 56%).[25,26]

Specific HPV types

In both the HIV-negative and HIV-positive groups, HPV 16 was the most prevalent hrHPV type, with almost one-third of patients infected. Disregarding HIV status, the most common hrHPV types identified were, in decreasing order of prevalence, HPV 16, 58, 35, 52, 51 and 31. This distribution differed from the meta-analysis, compared with both global and African data, on HPV type distribution in patients with cytological evidence of HSILs published in 2006.[27] The most common types of hrHPV among patients with CIN II or CIN III, as illustrated by a more recent meta-analysis, were HPV 16 followed by HPV 52, 58, 31, 45 and 33. There has been a worldwide increase in the prevalence of HPV 52 and 58 over the past 10 years.[28] Chen et al.[29] suggested that the long-term risk for developing cervical cancer was higher for HPV 58 than other non-HPV 16 types.

The just under 33% prevalence of HPV 16 in the entire study population is comparable to the prevalence reported by Guan et al.[30] for Africa (30.3%), which included both patients with CIN II/III and HSILs. The specific regions of Africa were not specified. The prevalence of just under 33% is also comparable to the global prevalence (34.7 - 52%) reported by Clifford et al.[31] for patients with HSILs. However, the prevalence of HPV 16 (32.9%) among HIV-infected patients in this study is lower than in other reports on HIV-positive patients from this study will be needed to evaluate this. This study also reported only on HPV DNA detection on the cervical surface and highlights the need to determine the specific HPV type or types incorporated within the specific lesion. Our unit is currently busy with a study comparing HPV types obtained from CIN lesions with surface HPV types.

Conclusion

In SA, burdened by the HIV pandemic, high numbers of high- and low-risk HPV type infections are present in women with cervical preneoplasia. The distribution of HPV types differs in HIV-infected patients. Administering the nine-valent HPV vaccine to women in our population may prevent as many as 80% of CIN II/III lesions. Future requiring HAART or having been receiving HAART for >12 months appear to be negatively associated with HPV 33, 59 and 82, and positively associated with HPV 73. Knowledge about the specific HPV type distribution is crucial to direct development of future HPV vaccines and to guide HPV-based screening in both HIV-infected and non-infected patients in this population.

References


Accepted 23 November 2015.